Technological requirements for adaptation

Article

Is it possible to adapt current femtosecond lasers to perform cataract surgery?

"There are five femtosecond laser systems on the market that perform their job pretty well in corneal surgery. They are femtosecond lasers, their interaction is based on photodisprution and they cut the cornea," he continued. "Recently we have had another group of femtosecond lasers become available that also perform photodisruption of the eye, however, these do not do it on the cornea but on the lens."

Looking into these systems further and trying to answer the question of adaptability, Prof. Lubatschowski examined the technological similarities and differences of the lasers.

"A similarity between these lasers is the photodisruption process," Prof. Lubatschowski said. Both use femtosecond pulse duration for this process, which is beneficial for precision - short pulses allow for higher precision. Using these femtosecond pulses in the range of nanoJoule to microJoule energy allows the lasers to reach the intensity threshold required to disrupt the relevant tissue without too large cavitation bubbles being formed and with much more control.

Additionally, the wavelength of the lasers are the same. "1000 nm is at least the cheapest wavelength available to produce femtosecond pulses and that's why all these lasers have wavelengths in that range, which is capable of penetrating the eye," he added.

Application of the lasers is a further similarity, with both requiring eye fixation and the patient-laser interface either being matched by moving the patient bed or the laser mirror arm of the system.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.